Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | FAAH | O00519 | 5/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20773925 | 1.00 | RECQL (0.52) | RECQLFAAHCNR1CNR2EPHX2 | |
| SCHEMBL8408859 | 0.98 | RECQL (0.54) | RECQLFAAHCNR1CNR2EPHX2 | |
| SCHEMBL29923901 | 0.97 | RECQL (0.52) | RECQLFAAHCNR1CNR2EPHX2 | |
| SCHEMBL6128361 | 0.95 | RECQL (0.51) | RECQLFAAHCNR1CNR2EPHX2 | |
| SCHEMBL27962924 | 0.94 | FAAH (0.51) | RECQLFAAHCNR1CNR2TP53 | |
| SCHEMBL11360975 | 0.94 | FAAH (0.51) | RECQLFAAHCNR1CNR2TP53 | |
| SCHEMBL6121600 | 0.94 | FAAH (0.50) | RECQLFAAHCNR1CNR2TP53 | |
| SCHEMBL10172884 | 0.93 | FAAH (0.52) | RECQLFAAHCNR1CNR2TP53 | |
| SCHEMBL19874781 | 0.93 | FAAH (0.52) | RECQLFAAHCNR1CNR2TP53 | |
| SCHEMBL28517090 | 0.91 | RECQL (0.53) | RECQLFAAHCNR1CNR2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4902344-A | Ferric chloride leach of a metal-sulphide bearing material | CANADIAN PATENTS & DEVELOPMENT LTD. (CA) | 1990-02-20 | — | — | US | claimed |
| EP-3848065-B1 | MEDICAL DEVICE WITH DRUG-ELUTING COATING AND INTERMEDIATE LAYER | BARD INC C R (US) | 2023-07-26 | — | — | EP | disclosed |
| US-11541152-B2 | Medical device with drug-eluting coating on modified device surface | LUTONIX INC (US) | 2023-01-03 | — | — | US | disclosed |
| US-11370996-B2 | Compositions including keto-ester compounds and methods of using the same | FOURTH PRINCIPLE, LLC (US) | 2022-06-28 | — | — | US | disclosed |
| US-20220176084-A1 | MEDICAL DEVICE WITH DRUG-ELUTING COATING ON MODIFIED DEVICE SURFACE | BARD PERIPHERAL VASCULAR, INC. | 2022-06-09 | — | — | US | disclosed |
| EP-3952937-A1 | MEDICAL DEVICE WITH DRUG-ELUTING COATING ON MODIFIED DEVICE SURFACE | Bard Peripheral Vascular, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| US-20210386917-A1 | MEDICAL DEVICE WITH DRUG-ELUTING COATING ON MODIFIED DEVICE SURFACE | LUTONIX INC (US) | 2021-12-16 | — | — | US | disclosed |
| EP-3880266-A1 | MEDICAL DEVICE WITH DRUG-ELUTING COATING ON MODIFIED DEVICE SURFACE | Lutonix, Inc. (US) | 2021-09-22 | — | — | EP | disclosed |
| EP-3848065-A1 | MEDICAL DEVICE WITH DRUG-ELUTING COATING AND INTERMEDIATE LAYER | C.R. Bard, Inc. (US) | 2021-07-14 | — | — | EP | disclosed |
| US-20210154372-A1 | MEDICAL DEVICE WITH DRUG-ELUTING COATING AND INTERMEDIATE LAYER | C.R. BARD, INC. | 2021-05-27 | — | — | US | disclosed |
| EP-0585355-B1 | MULTI-LAYERED CONTROLLED RELEASE FORMULATION | MARION LABORATORIES INC (US) | 1995-03-22 | — | — | EP | disclosed |
| US-5320853-A | Multilayer core and multilayer periphery, sustained release coating | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-06-14 | — | — | US | disclosed |
| US-5166259-A | Polymers for textiles on substrates | GENCORP INC. (US) | 1992-11-24 | — | — | US | disclosed |
| US-4956495-A | Formation of amides substituted with hydroxyalkylacids by reaction in the presence of an acid catalyst of the amide and an aldehyde-acid | GENCORP. INC. (US) | 1990-09-11 | — | — | US | disclosed |
| US-4954564-A | Process for preparing unsaturated nitrogen containing acids | GENCORP INC. (US) | 1990-09-04 | — | — | US | disclosed |
| US-4902344-A | Ferric chloride leach of a metal-sulphide bearing material | CANADIAN PATENTS & DEVELOPMENT LTD. (CA) | 1990-02-20 | — | — | US | disclosed |
| US-4808660-A | LOW TEMPERATURE CURABLE, TENSILE STRENGTH | GENCORP INC. (US) | 1989-02-28 | — | — | US | disclosed |
| US-4634730-A | VINYL OR VINYLIDENE CHLORIDE POLYMER LATEX FOR BACKING | GENCORP INC. (US) | 1987-01-06 | — | — | US | disclosed |
| US-4595617-A | Applying to back of carpet a latex of polyvinylidene chloride, polyvinyl chloride, copolymers thereof, and an ethylenically unsaturated monomer, plasticizer, filler; heating, impregnating carpet, compressing | GENCORP INC. (US) | 1986-06-17 | — | — | US | disclosed |
| US-4411933-A | CYCLOHEXANE, ORGANOSILICON POLYMER, DISPERSION, CORES | TANABE SEIYAKU CO., LTD. (JP) | 1983-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220176084-A1 | MEDICAL DEVICE WITH DRUG-ELUTING COATING ON MODIFIED DEVICE SURFACE | ERP44, EGFR, KDELR2 | RECQL 4181/4885FAAH 1884/4885CNR1 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.